HomeREGULATORY
REGULATORY

Daiichi Sankyo's Herceptin Biosimilar Now in Line for September Approval as It Clears MHLW Panel
(Aug.6.2018)

Daiichi Sankyo’s Herceptin (trastuzumab) biosimilar cleared a key health ministry advisory panel on August 3, opening the way for approval both in gastric and breast cancer indications in September and NHI reimbursement listing in November, if all goes well ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar